UNSPSC 51332306: Neflumozide hydrochloride

This classification denotes a dopamine antagonist with the molecular formula C22H23FN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SU2C8RYO3O, chemically known as 1-(1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-piperidyl)-3h-benzimidazol-2(1h)-one hydrochloride but more generally known as neflumozide hydrochloride, which bears US NIH Compound Identifier 55463. Most nations, for tariff and trade purposes, schedule neflumozide hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, NEFLUMOZIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Neflumozide hydrochloride bears US NLM identifiers UMLS ID C2827280 and NCI Concept Code C83993. SMILES: C1CCC2C(C1)[NH]C(=O)N2C3CCN(CC3)CCCC4C5CCC(CC5ON4)F.CL.

UNSPSC 51332306 Neflumozide hydrochloride is a Commodity code that shows little relevant recent activity. The three recent opportunities posted under this code — Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer prescriptions, and MMCAP's generic pharmaceuticals contract — do not align with neflumozide hydrochloride specifically. Neflumozide hydrochloride is a pharmaceutical active ingredient with a narrow therapeutic scope; the solicitations retrieved instead reflect broader pharmaceutical procurement, including emergency response medications (naloxone), pharmacy benefit program innovation, and multi-state cooperative purchasing of generic drugs and over-the-counter products. The mismatch suggests either that the code is rarely used for actual state and local procurements in this category, or that issuers are tagging pharmaceutical opportunities with broader or adjacent codes rather than this specific commodity designation.

Recent pharmaceutical solicitations at the state and local level involve county health departments, state human services commissions, and multi-state cooperative purchasing alliances (MMCAP, representing Minnesota, Oregon, and other participants). Issuing bodies range from single-county health systems to statewide procurement offices administering cooperative agreements. Geographic activity appears concentrated in the Southeast (Florida) and Midwest (Minnesota, Oregon), with Texas HHS pursuing exploratory market research on prescription-fulfillment models. The Seminole County naloxone procurement (IFB60459723LAS, due July 26, 2023) sought 1,900 units annually through competitive bidding; the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals across multiple states through authorized wholesalers; and the Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered vendor capability information on direct-to-manufacturer contracting models. If your firm supplies neflumozide hydrochloride or active pharmaceutical ingredients to state and local health systems, this code warrants direct outreach to county procurement offices and state pharmacy benefit programs rather than reliance on coded opportunity feeds.